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Psoriatic Arthritis (PsA) is a chronic inflammatory form of Arthritis associated with enthesitis, 
dactylitis, nail dystrophy, uveitis, and osteitis.  PsA is strongly associated with comorbidities 
such as obesity, metabolic syndrome, and cardiovascular disease. As usual PsA patients are 
assessed either by rheumatologist or dermatologist but a multiprofessional assessment for those 
subjects is important to improve their disease control and their quality-of-life.  The 
multidimensional assessment is a new model of care for PsA patients in which a 
multiprofessional team (rheumatologist, dermatologist, internal medicine physician, 
nutritionist and a phycologist) with a nurse as case manager, assess patients in the main domains 
of PsA from the admission to the follow-up. Different validated tools are used by the team to 
assess different patients’ dimension as patient-reported-outcomes. This study aimed to evaluate 
the association between and among clinical variables and Patient-Reported Outcomes in a real-
world sample of PsA patients evaluated according the Multidimensional Assessment.    
Methods 
A cross-sectional study was conducted. Patients with PsA who signed the informed consent 
were enrolled at the PsA clinic at the ARNAS Civico in Palermo (Italy) from March 2018 to 
October 2020. Clinical, pharmacological, anthropometric, laboratory variables, and patient-
reported outcomes were evaluated, including:  
• Health Assessment Questionnaire (HAQ); 
• Facit-Fatigue (FACIT-F);  
• Psoriatic Arthritis Impact of Disease Questionnaire (PsAID);  
• Patient Health Questionnaire-9 (PHQ-9); 
• Disease Activity in PSoriatic Arthritis score (Dapsa);  
• Patient global assessment (PGA) 
STATA 14.1 was used to perform logistic analysis.   
 
Results 
According to CASPAR Criteria, 158 patients aged 55.2 (53.3 – 57.1) affected by Psoriatic 
Arthritis were included in the study. All the collected variables were evaluated ad a strong 
association was observed between functional disability measured by HAQ >2 and central 
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obesity [OR (95% CI) 16.94 (2.22 - 129.48); p < 0.004]. Moreover, data analysis showed an 
association between high impact of disease on life (PsAID >4) and central obesity [OR (95% 
CI) 3.33 (1.56 - 7.13); p<0,002]. Models were adjusted for age, sex, years of illness, and 




This study demonstrated a high association between functional disability studied subjectively 
using the HAQ, the impact of the disease on patients’ quality-of-life using the PsAID, and 
central obesity in patients affected by PsA. Data suggest that a multiprofessional evaluation for 
these patients is important to evaluate different aspect of the disease as the comorbidities. In 
particular, therapeutic goals should not be focused only on treatment but also on waist 





















Psoriatic Arthritis (PsA) is a chronic, immune-mediated, inflammatory spondyloarthropathy 
pathogenetically associated with Psoriasis. Patients affected by PsA commonly suffer from 
sleep disorders, fatigue, low-level stress, depression, mood changes, and anxiety that contribute 
to high rates of absenteeism from work, productivity loss, and unemployment, especially in the 
first 2-5 years of disease. With this combination of pain, disability, skin disease, fatigue, and 
poor quality of life, PsA confers considerable psychosocial and functional burden on patients 
[1-6].  
The global epidemiology of PsA differs depending on the population and the criteria utilized.  
In the general population, PsA has a prevalence of 0.05% to 0.25%, affecting up to 30% of 
patients with Psoriasis [7-8]. The prevalence is similar among women and men between 30 and 
40 years [9], and there are a higher prevalence and incidence rate in Europe and North America 
than in Asia [10-12]. PsA presents with a varied disease course whose type of tissue 
involvement can change over time as inflammation of the joints and entheses, including those 
of the axial skeleton and it is associated with increased mortality from cardiovascular disease 
[13]. PsA contributes to deformities and joint damage in most patients, with bone erosion often 
developing in the first two years of the disease. For many years it was classified as a variant of 
Rheumatoid Arthritis (RA) but radiological, clinical, and laboratory data have established PsA 
as a distinct, progressive articular entity with the potential to impair function, reduce the quality 
of life and increase mortality [14]. In the past, PsA was usually underdiagnosed and 
undertreated, particularly in the primary care environment, in fact many clinicians in primary 
care and dermatology settings were unaware of the risk for musculoskeletal disease in patients 
with Psoriasis. The need for regular screening for PsA was underestimated, but early 






Chapter 1: Psoriatic Arthritis  
1.1 Pathogenesis, genetic and environmental triggers 
Various genetic, immunological and environmental triggers predispose patients to develop 
Psoriatic Arthritis and Psoriasis. PsA is a highly heritable disease with a prevalence of 19.7% 
(95% CI, 18.5%-20.9%) in patients with Psoriasis [16]. A range of genetic factors may 
contribute to this strong familial component, including frequencies of major histocompatibility 
complex (MCH) class II alleles such as human leukocyte antigens (HLA)-B*08, B*27, and 
B*38. Nearly 25% of patients with PsA are positive for human leukocyte antigen (HLA)-B 27. 
Different PsA manifestations are associated with specific HLA alleles, including symmetric 
sacroiliitis (HLA-B 27:05), enthesitis (HLA-B 27:05 and HLA-C 01:02), asymmetric 
sacroiliitis (HLA-B 08:01 and HLA- C 07:01), dactylitis (HLA-B 27:05 and HLA-B 08:01), 
and synovitis (HLA-B 08:01) [17].  
Several environmental factors have been implicated in Psoriatic Arthritis’ triggering, with the 
production of IL-23, by putting stress on joints in genetically susceptible subjects. Some of 
these factors include (Table 1): 
• Obesity: obesity may be a predisposing factor for PsA in people affected by Psoriasis, 
and PsA might also predispose to obesity by reducing physical activity because of 
functional and or psychological limitations [18]. Visceral adipose Tissue was 
considered to be a storage organ for fatty acids without other functions, but nowadays, 
in particular, the visceral one is considered a metabolically active endocrine organ [19-
21]. It represents a source of inflammatory mediators, known as adipokines including 
leptin and adiponectin, plasminogen activator inhibitor-1 (PAI-1), TNF-α, macrophage 
chemoattractant protein-1, IL-6, leading to a pro-inflammatory status in obese subjects. 
Adiponectin is an anti-inflammatory cytokine and could exert protective effects in 
obesity-related metabolic and vascular diseases, presumably due to its anti-
inflammatory action. In subjects with inflammatory diseases, high levels of cytokines 
such as TNFα or IL-6 may further reduce adiponectin synthesis by adipose tissue, in 
fact low serum levels of adiponectin are frequently reported in patients with obesity or 
Psoriasis. [22] For all these reasons, obesity is considered a low-grade inflammatory 
disease. In particular, central obesity may also determine an increased risk of not 
achieving and maintaining minimal disease activity (MDA) in PsA patients [23], 
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highlighting the role of central fat accumulation as a negative predictor of good clinical 
response to treatment, especially the response to TNFα- blockers [24]; 
• Nail Involvement: nail involvement as onycholysis and psoriatic nail pitting; were 
associated with an increased risk for PsA [25]; 
• Smoking: smoking appears to increase the risk of developing Psoriatic Arthritis in 
healthy controls but not in patients with Psoriasis. Smoking has been suggested to be 
protective in Psoriasis (the so-called smoking paradox) an effect related to 
polymorphisms in the IL13 gene. However, methodological limitations might explain 
this observation [26];	
• Alcohol: Excessive ethanol consumption contributes to the increased levels of tumor 
necrosis factor (TNF)-α-converting enzyme (TACE) and transforming growth factor 
(TGF)-α receptor 1, which are involved in systemic immunodysregulation in Psoriasis. 
Epidemiologic evidence suggests that alcohol intake is associated with a risk of incident 
PsA in women [27]; 
• Bacterial and viral infections: The role for infection as a gene–environment 
interaction was analyzed by observing and increasing the prevalence of streptococcal 
antibodies in patients with Psoriatic Arthritis. The increased incidence of Psoriatic 
Arthritis in HIV-endemic populations of Sub-Saharan Africa suggests roles for both 
infection and T cells. HIV-associated depletion of CD4-positive T cells has been shown 
to induce remission of Rheumatoid Arthritis, but induced acute onset or exacerbation 
of Psoriatic Arthritis. It is unclear whether psoriatic disease is directly triggered by viral 
infection; or by the depletion of CD4-positive T and CD8-positive T cells’ 
predominance; 
• Trauma: Trauma (known as the Koebner phenomenon) is a known factor in psoriatic 
skin lesions. Heinrich Koebner (1838–1904) reported the emergence of new psoriatic 
lesions in the healthy skin region (non-involved by Psoriasis) following an 
injury/trauma to the healthy skin areas of psoriatic patients [28]; 
• Microbiome: new evidence suggests that the microbiome may play a pathogenic role 
in psoriatic disease. The possible role of the microbiome in the gene–environment 
interaction in Psoriasis and PsA was showed in different studies. As for by studying the 
faecal bacteria in patients with Psoriatic Arthritis compared with healthy controls, there 
were significant reductions in Firmicutes, Bacteroidetes and Actinobacteria in psoriatic 
individuals [29]. The composition of the psoriatic microbiome is unknown. The skin 
microbiome was analyzed in different studies showing a decreased relative abundance 
of Propionibacterium in psoriatic lesional skin [30-33]. Loss of Propionibacterium, 
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which is one of the major components of normal skin microflora, can lead to decreased 
immune tolerance and an increased propensity for psoriatic inflammation.  
 
Tab.1 Risk factors for the development of PsA. 
 
Some PsA patients have more than one comorbid condition in addition to the skin and joint 
diseases. PsA is strongly associated with different comorbidities including cardiovascular 
disease, metabolic syndrome, obesity, diabetes mellitus, dyslipidemia, inflammatory bowel 
disease, fibromyalgia, fatty liver disease, uveitis, kidney disease, infections, osteoporosis, 
depression, central sensitization syndrome, and gout [34]. In particular, cardiovascular disease 
is one of the most important causes of death in PsA patients due to the fact that inflammatory 
state, with high serum levels of circulating interleukin (IL)-17, interferon-alpha and TNF, 
promotes vasoconstriction and endothelial dysfunction which may lead to plaque formation 
accelerating the progression of atherosclerosis. TNF is also overexpressed in the adipose tissue 
that links obesity, diabetes and the chronic inflammation that drives also metabolic syndrome.		
Serum cytokines are the main actors of the chronic ‘low-grade’ inflammatory state of psoriatic 
disease which lead to the most important comorbidities.  
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1.2 The Role of the Cytokines 
Psoriatic Arthritis (PsA) is a complex heterogeneous disease with a complex pathophysiology. 
Also, if the molecular and cellular interactions between skin and joint disease have not been 
well characterized, novel therapeutics targeting different cytokines (IL-12, IL-23, IL-17, IL-17 
receptor, TNF) are effective in treating both the skin and joint manifestations in PsA. In fact, in 
patients affected by PsA innate and adaptive cells and some pro-inflammatory cytokines are 
involved, in particular the interleukin 23/17 axis [35].  
Serum cytokines play an important role in Psoriatic Arthritis’ pathogenesis by initiating and 
perpetuating various cellular and humoral autoimmune processes. Interleukins are involved in 
the mechanism of inflammation in PsA, but the pathogenic link between the inflammatory T 
cell responses of Psoriasis and the joint inflammation of PsA is unclear.  
It has been hypothesized that PsA is triggered by autoinflammatory cytokine networks that 
respond to some environmental stressors.  
There are several complex interactions between activated CD4+ T-cells, CD8+ T-cells, 
lymphocytes, and macrophages in the IL-23/IL-17 immune axis that result in 
osteoclastogenesis, bone resorption, and cartilage destruction in patients affected by PsA. 
Moreover, the Janus-Kinase (JAK) family of receptor-associated tyrosine kinases are 
implicated in the pathogenesis of PsA. JAKs activate signal transducer and activator of 
transcription (STATs) depending on the cytokine signal they receive and inhibit several pro-
inflammatory cytokines, including IL-6, IL-12, and IL-23.  
TNF was one of the earliest cytokines to be identified in the pathogenesis of PsA; it is produced 
by several types of immune cells and activates key effector cells involved in tissue 
inflammation.  
Increased circulating T helper 17 (Th17) cytokines have been detected in patients’ peripheral 
blood with PsA. Th17 pathways may stimulate the release of inflammatory substances such as 
interleukin (IL)-12, IL-17, IL-22, IL-23, and TNF and, in particular, IL-17 has been found in 










Fig 1 Mechanisms of inflammation in Psoriasis and PsA 
 
Generally, in case of tissue damage or autoimmune stimuli the body protects itself with an 
inflammation response consisting of a cascade of chemicals and cytokines in the affected area.       
T-cell subpopulations Th1, Th2, Th17, Th9, Th22, and Treg cells secrete pro-inflammatory or 
anti-inflammatory cytokines. Dendritic cells, macrophages, ILCs, MAIT cells, NK cells and 
mast cells produce mostly pro-inflammatory cytokines. These pro-inflammatory mediators 
activate resident cells, including synovial fibroblasts, chondrocytes, osteoblasts, and 
osteoclasts, which in turn secrete more pro-inflammatory mediators that can further recruit 
immune cells into the joints, creating a self-perpetuating inflammatory response. Additionally, 
synovial fibroblasts secrete matrix-degrading enzymes and receptor activator of nuclear factor-
kappa-Β ligand (RANKL), resulting in cartilage degradation and bone resorption. The inflamed 
synovial microenvironment leads to the formation of the synovial pannus, entheseal 






























Fig 3 Key cytokines in Psoriatic Arthritis  
 
 
In PsA some of the most important cytokines are:  
• IL-17: IL-17 family consists of six proteins of the adaptive and innate immunity (IL-
17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F). IL-17 is produced by T (17) cells, 
γδ T cells, natural killer T (NKT) cells, NK cells, and type 3 innate lymphoid cells and 
plays a significant role in the development of both Psoriasis and PsA. IL-17 can induce 
the production of pro-inflammatory cytokines, such as IL-6, IL-1, GM-CSF, G-CSF.  
• IL-17A: is a member of the IL-17 cytokine family. IL-17A producing T cells can be 
protective for the organism as for skin infections or cause tissue damage. It is implicated 
in the pathogenesis of inflammatory autoimmune diseases like Psoriasis. Psoriatic skin 
is characterized by high expression of IL-17A and IL-17F, which act on immune and 
non-immune cell types and strongly contribute to tissue inflammation. As confirmed in 
many studies, psoriatic skin is characterized by high expression of IL-17A, IL-17F and 
Il-17E. For instance, they are involved in neutrophil recruitment. In the skin of psoriatic 
lesions, neutrophil accumulation is followed by the formation of epidermal micro 
abscesses. IL-17A and other Th17 cytokines upregulate the production of several 
chemokines implicated in Psoriasis pathogenesis. Psoriasis skin manifestations, 
cardiovascular, and metabolic disease in Psoriasis appear to share pathogenic 
mechanisms evolving around IL-17A and its pro-inflammatory role [36].  
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• IL-23: IL-23 has been implicated in the proliferation and maintenance of IL-17. It 
regulates the secretion of IL-17, IL-21 and IL-22 by Th17 cells which mediate the 
epidermal hyperplasia, the keratinocyte differentiation in Psoriasis.  
• The IL-23/IL-17 axis: is critical in regulating cytokine network and inflammatory 
mediators contributing in the pathogenesis of Psoriasis. The interleukin (IL)-23– IL-17 
axis plays a critical role in osteoclastogenesis.   
• Serum cartilage oligomeric matrix protein (COMP): is a biomarker for cartilage 
degradation. COMP has been identified in cartilage, ligaments, meniscus, tendons, 
synovium, osteoblasts and vascular smooth muscle. COMP has potential as a diagnostic 
and prognostic indicator and it is a valuable tool to the identification of patients at high 
risk for rapid joint destruction and monitoring treatment efficacy [37]. 
• IL-2: IL-2 is a member of a cytokine family that includes IL-4, IL-7, IL-9, IL-15, IL 
21. L-2 has essential roles in the immune system’s key 
functions, tolerance and immunity, primarily via its direct effects on T cells. In 
the thymus, where T cells mature, it prevents autoimmune diseases by promoting 
the differentiation of certain immature T cells into regulatory T cells, which suppress 
other T cells otherwise primed to attack normal healthy cells in the body.  Some 
evidence indicates that IL-2 is involved in itchy Psoriasis [38].  
• IL-4: It has an anti-inflammatory action, in fact IL-4 can inhibit the production of pro-
inflammatory cytokines such as TNF-α, IL-1 and IL-6. Moreover, it has inhibitory 
action of the synoviocytes proliferation, reducing collagenase synthesis. 
• IL-6: also called B-cell stimulatory factor-2 (BSF-2) causes increased body temperature 
in acute inflammatory phase. Serum IL-6 has been found in patients with PsA versus 
skin disease alone, correlating with the number of joints affected. However, this 
cytokine is not a specific screening tool.  
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• IL-12: In PsA pathophysiology, IL-12 promotes the differentiation of naïve CD4+ T 
cells into mature IFNγ-producing T-helper type 1 (Th1) effector cells. It is also a potent 
stimulus of natural killer cells and induces CD8+ T cells to produce IFNγ. IL-12 has 
been shown to play a protective role against the development of PsA [39-40]. IL-12 has 
an anti-inflammatory effect on joints. Therefore, IL-12 is significant to PsA 
development through its inactivation, or its association with the p40 subunit. 
• IL-8: Like IL-6, IL-8 can be secreted by cells with Toll-like receptors in response to 
pathogens’ stimulation.  IL-8 recruits neutrophils and other target cells through 
chemotaxis.   
• IL-10: it has a role in immunoregulation and inflammation. It downregulates the 
expression of Th1 cytokines, MHC class II antigens, and co-stimulatory molecules 
on macrophages. It also enhances B cell survival, proliferation, and antibody 
production.  
• Macrophage colony-stimulating factor (M-CSF): circulating M-CSF concentrations 
are elevated in the patients with erosive PsA and are correlate with severity of the 
peripheral erosive disease [41].  
• RANK/RANKL Receptor activator of nuclear factor κB (RANK) is associated with 
bone metabolism and promotes osteoclastogenesis. RANKL receptor has been founded 
on epidermal dendritic cells and can causes increased proliferation of CD4+CD25+ T 
cells.  
• TNF alpha: is a key pleiotropic inflammatory cytokine.  It has both growth promotion 
and inhibition effect to some cells. TNF-α initiates a cascade of cytokines in the local 
inflammatory immune response and increases vascular permeability recruiting 











1.3 Diagnosis and clinical features 
Clinicians in dermatology, rheumatology and primary care clinics play an important role in 
screening psoriatic patients for PsA on time to improve patients’ quality of life. Patients with 
Psoriasis typically present first to a dermatologist because arthritis is rarely noted initially, and 
PsA is often unrecognized until patients consult with a rheumatologist. The reasons why 
Psoriatic Arthritis sometimes remains unidentified are not clear but might include insufficient 
musculoskeletal expertise among primary care physicians and dermatologists. Early diagnosis 
in rheumatology in people with Psoriasis can enable earlier treatment of this disabling disease 
and prevent unnecessary suffering but can be challenging when arthritis is present without skin 
lesions. Patients with PsA often have a family history of psoriasis or PsA, but in patients with 
classic clinical features of PsA but no history of Psoriasis, it is important to examine the 
patient’s scalp, skin, and nails. The diagnosis of PsA is clinical and based on patient history and 
physical examination and supported by imaging and laboratory evaluation. 
PsA can manifest in up to six different clinical domains: 
• Peripheral arthritis: peripheral arthritis can classify as oligoarticular, polyarticular, and 
isolated distal interphalangeal joint (DIP) inflammation. Polyarticular PsA symmetrically 
involves ≥5 joints, instead oligoarthritis, involves <5 joints in an asymmetrical 
distribution.    
• Axial disease: is characterized by back pain persisting for >3 months before age 40 years, 
alternating buttock pain (caused by sacroiliitis), pain causing waking from sleep during 
the second half of the night and prolonged morning stiffness or stiffness upon immobility;	 
• Dactylitis: inflammation of an entire digit that may be red, hot, and tender or swollen. 
Dactylitis can occur in isolation or as one of several digits affected. On examination, 
palpation of distal joints typically reveals soft swelling and tenderness due to 
inflammation; 
• Enthesitis: inflammation of the connective tissue between tendon or ligament and bone;  
• Skin and nail disease: skin can be affected psoriasis; nails matrix can be characterized 
by nails’ pitting, Beau’s lines, onychomadesis, trachyonychia, nail dystrophy and 
leukonychia. Nail bed leads to onycholysis, oil drop patches, subungual hyperkeratosis 
and splinter hemorrhages [42-43].  
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At the time, there are no widely accepted diagnostic criteria for PsA. The first classification 
criteria for PsA were the Moll and Wright criteria, which defined Psoriatic Arthritis as 
inflammatory arthritis occurring in the presence of Psoriasis but with an absence of rheumatoid 
factor on serological tests. In 2006 The Classification of Psoriatic Arthritis (CASPAR) criteria 
was developed and included the presence of inflammatory articular disease (joint, spine, or 
entheseal), with typical features such as Psoriasis (current, or personal or family history), 
psoriatic nail dystrophy, absence of rheumatoid factor, dactylitis (current or personal history), 
and radiological evidence of new juxta-articular bone formation providing additional points to 
yield a definitive classification [44]. To meet the CASPAR criteria, patients must have signs of 
inflammatory articular disease (joint, spine, or enthesial) with at least 3 points from the five 
categories (Table 3). To date, radiographic imaging with power doppler ultrasound is the gold 
standard for establishing joint damage in PsA, and it is used to find erosive changes in 
peripheral joints. For the diagnosis of PsA there are no specific serologic tests, but the elevation 
of acute phase reactants (ESR, CRP) may be found in ~40% of PsA patients. PsA is also 
associated with systemic diseases such as hypertension, type 2 diabetes, obesity, metabolic 
syndrome, fatty liver disease, autoimmune disease, malignancies, and cardiovascular disease.  
Table 2 CASPAR Criteria. Psoriatic Arthritis is considered to be present in patients with inflammatory 




Therapy in PsA aims to limit skin and joint symptoms and signs, prevent or slow structural 
damage and complications, maintain health-related quality of life and achieve the lowest 
possible disease activity level in all domains of the disease.  Different drugs are used to treat 
patients affected by PsA including: non-steroidal anti-inflammatory drugs (NSAIDs), synthetic 
disease-modifying anti-rheumatic drugs (DMARDs), biologic therapies, biosimilar or the novel 
small molecules [45]: 
§ Non-steroidal anti-inflammatory drugs (NSAIDs) are used in patients with mild 
symptoms or limited joint involvement and, in the case of inflamed joints, intraarticular 
corticosteroid injections may be recommended. The EULAR guidelines recommend 
that systemic glucocorticoids may be used with caution at the lowest effective dose for 
the shortest possible period.  
§ DMARDs: i.e., methotrexate (MTX), sulphasalazine, cyclosporine, leflunomide, are 
systemic therapy recommended for patients with three or more inflamed joints or in 
patients with persistent axial, entheseal, or dactylic disease: 
o Methotrexate (MTX) is a folic acid analogue with anti-inflammatory effects 
mediated primarily through neutrophils, T cells, and monocytes/macrophages.  
MTX has been commonly prescribed as first-line therapy to reduce joint 
tenderness and swelling by increasing adenosine release (an anti-inflammatory 
agent) at the sites of inflammation and by releasing pro-inflammatory cytokines 
responsible for inflammation in PsA.  Early treatment with MTX is associated 
with mild inhibition of joint damage progression and improved health-related 
quality of life. Methotrexate is effective in treating cutaneous Psoriasis but not 
in improving psoriatic nail disease or enthesitis, dactylitis or axial arthritis. Not 
all patients respond to MTX, in fact patients affected by entheseal disease and 
spinal inflammation are more responsive to anti-TNF agents than to DMARDs; 
o Sulfasalazine is effective in treating peripheral arthritis and axial involvement 
in PsA, but it is not effective in arresting the progression of clinical and 
radiologic damage;  
o Leflunomide is an oral disease-modifying agent that reduces synovitis by 
inhibiting dihydroorotate dehydrogenase, an enzyme necessary for the 
production of DNA and RNA. There are few studies on the efficacy of this drug 
in enthesitis and axial PsA; 
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o Cyclosporine: this drug has modest efficacy for nail Psoriasis. Data on its 
efficacy in enthesitis, dactylitis or axial disease are insufficients, and there is no 
evidence that cyclosporine reduces radiographic progression in patients with 
PsA. 
o Other csDAMRDs as azathioprine, gold and hydroxychloroquine are less used 
in patients affected by PsA.   
§ Biologics (Fig 4) are monoclonal antibodies that target interleukin pathways, modulate 
T cells, and inhibit JAK pathways. Biologics are named according to a specific 
nomenclature in fact: 
o “-cept” refers to the fusion of a receptor to the Fc part of human immunoglobulin G1 
(IgG1) 
o “-mab” indicates a monoclonal antibody (mAb) 
o “-ximab” indicates a chimeric mAb 
o “-zumab” indicates a humanized mAb 
 






According to EULAR guidelines, patients with active disease (i.e., a high number of active 
joints, high inflammatory markers, and ongoing joint damage) should be treated with biologics 
after the failure of one DMARD. TNF inhibitors have demonstrated efficacy in treating skin 
and joint involvement as well as in preventing radiographic damage. However, they are 
associated with a broad spectrum of hematologic and metabolic adverse events (e.g., 
opportunistic infections such as tuberculosis, cytopenia, lymphoma, heart failure, and 
hepatotoxicity) so patients should be assessed before to start this kind of therapies. Biologics 
are: 
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o Infliximab: is a mouse/human chimeric anti-TNF that improves Psoriasis severity, 
enthesitis, dactylitis, nail Psoriasis, axial disease and peripheral joint radiographic 
progression; 
o Adalimumab: is a fully human anti-TNF monoclonal antibody. It improves Psoriasis 
severity, symptoms of axial disease and nail Psoriasis and can treat patients affected by 
bowel diseases;  
o Golimumab: as Adalimumab it is also a fully human inhibitor of tumor necrosis factor 
alpha. It improves enthesitis, dactylitis, Psoriasis and nail disease;  
o Certolizumab pegol: is a PEGylated Fab fragment anti-tumor necrosis factor alpha 
antibody approved for the treatment of PsA; 
o Etanercept: is a human anti-TNF. It improves physical function in patients with 
Psoriatic Arthritis, and reduces the progression of peripheral joint damage as measured 
by X-ray.  
 
Various biologics as secukinumab, ixekizumab, and brodalumab target either IL-17 or IL-17R 
and are recommended for patients affected by PsA: 
o Secukinumab: is a fully human, high-affinity anti-IL-17A monoclonal antibody. It 
reduces radiographic progression of the disease and improves Psoriasis, nail disease, 
enthesitis and dactylitis; 
o Ixekizumab is a humanized IgG4 monoclonal antibody that neutralizes interleukin-
17A. It improves Psoriasis, nail disease, enthesitis, dactylitis and reduces reduced 
radiographic progression of joint damage; 
o Brodalumab: a fully human anti-IL17R monoclonal antibody. It improves dactylitis,  
Psoriasis and nail disease.  
Research on the IL-23/IL-17 axis has provided drugs as the IL-23 blocker Ustekinumab and 
Guselkumab: 
o Ustekinumab: is a monoclonal antibody that inhibits interleukin IL-12 and IL-23 
important cytokines in the pathogenesis of psoriatic disease. Ustekinumab can be 
administered as monotherapy or in combination with MTX. It improves Psoriasis, 
enthesitis, dactylitis and nail disease and physical functioning and decreases 
radiographic progression in the hands/feet of patients affected by PsA; 
o Guselkumab: is an interleukin-23 inhibitor approved in Psoriatic Arthritis that also 
reduces patients’ fatigue; 
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o Clazakizumab: it is an IL-6 monoclonal antibody with high affinity and specificity for 
IL-6. It may be effective on the musculoskeletal manifestations of PsA, but further 
studies need to be undertaken;  





Biosimilars are biologic drugs designed to have similar active properties to ones that have 
been already licensed. The EMA approved biosimilars to date are Benepali (etanercept), Erelzi 
(etanercept), Amgevita (adalimumab), Inflectra (infliximab), Remsima (infliximab) and some 
others. The lower cost of these drugs may make them more accessible, especially in resource-
poor settings in terms of access may be addressed.  
 
§ JAK inhibitors: 
o  Tofacitinib: it is an oral JAK inhibitor. Activated JAKs are pro-inflammatory and 
recruit and activate signal transducer and activator of transcription (STATs), which 
drives gene transcription. It inhibits JAK1 and JAK 3a and was approved in 2017 for 
adults with active PsA who do not respond to DMARDs. 
o Small molecule: Phosphodiesterase 4 inhibitor (PDE 4-I) Apremilast (Otezla) is an oral 
phosphodiesterase 4 (PDE 4) inhibitor that has demonstrated clinical benefit for patients 
with PsA and is now FDA-approved for patients with active PsA. Apremilast is a well-
tolerated drug with a safety profile. Apremilast improves enthesitis and nail Psoriasis, 








Chapter 2. A New Model of PsA Care: The Multidimensional 
assessment of PsA patients 
The early recognition and diagnosis of PsA is significant to ensure that patients with PsA have 
successful access to the treatment options. However, clinicians in primary care do not always 
screen the patients with Psoriasis for PsA and do not always refer patients for evaluation by a 
rheumatologist. Patients affected by Psoriatic Arthritis should be assessed both from 
rheumatologists and dermatologists with other healthcare professionals’ support to improve 
patients’ disease control and their quality of life. Health professionals should provide integrated 
and multidisciplinary care in which nurses are fundamental. The role of the nurses in 
rheumatology is changing. More and more specialized rheumatology nurses in the world have 
an important role of case managers for patients affected by rheumatic diseases. While at time 
in Italy rheumatology as a nursing specialty does not exist, specialized nurses in other countries 
act as the interface between patients and the other multidisciplinary team members helping to 
reduce their workload significantly. Nurses assess patients from the evaluating the symptoms 
to the diagnosis and the follow-up and have important roles for rheumatic patients. The work 
of a specifically trained nurse in rheumatology includes self- management support, the 
monitoring of disease consequences on life and patient education and counselling [46]. In 
particular, nursing education is important because PsA has consequences on daily activities and 
participation in society including productivity and employment [47] and evidence suggests that 
patients who are given educational advises on their condition by the nurses are better able to 
cope with the physical and psychological challenges of this rheumatic disease [48]. A 
multidisciplinary and multidimensional assessment made by different healthcare professionals 
in a dedicated setting is the best model for assessing patients who meet CASPAR Criteria. A 
nurse specialist coordinates the process to allow patients to have a more comprehensive 
assessments in a short period and the same setting. The multidimensional assessment includes 
a standardized evaluation of disease severity, patient-reported outcomes and treatment in both 
rheumatology and dermatology practice. The multidisciplinary team is made by a nurse 
specialist, an internal medicine physician, a dermatologist, a rheumatologist, a nutritionist and, 
in case of depression, a psychologist who assess patients from the first evaluation to the follow-
up. Each actor of the process is important to evaluate the patient multidimensionally. The first 
clinical assessment is done by an internal medicine physician who assesses medical history, 
lifestyle and patient’s health status investigating comorbidities and polytherapy using the 
Cumulative illness Rating Scale and the Polytherapy record. According to the Group for 
Research and Assessment of Psoriasis and PsA (GRAPPA), in the multidimensional evaluation 
 24 
patients are assessed by physicians in the six main domains: peripheral arthritis, skin and nail 
disease, axial arthritis, enthesitis and dactylitis for the appropriate management of disease 
activity [49]. After the first evaluation, disease activity is evaluated by physicians to assess the 
effectiveness of therapy [50]. Due to this, the rheumatologist assesses the six main domains 
together with the dermatologist. The rheumatologist uses the 68/66 tender and swollen joint 
count for the Disease Activity in PSoriatic Arthritis (DAPSA) score to evaluate peripheral 
arthritis while the axial arthritis is evaluated by the Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI). The rheumatologist also evaluates patients’ enthesitis (defined as 
the inflammation at the areas of insertion of the tendons, ligaments and joint capsules to the 
bone) and dactylitis (inflammatory swelling of the entire digit including bone, tendon sheaths, 
articular and peri-articular tissues). The dermatologist evaluates skin with the Psoriasis area and 
severity index (PASI). The PASI is a quasi-objective measure that scores the average redness, 
thickness, and scaling of the lesions (0–4 scale), weighted by the area of involvement. PASI 
scores range from 0 to 72, where higher scores indicate severe disease. Nails are evaluated by 
the nail Psoriasis severe index (NAPSI). The nutritionist evaluates, with the Bio-Electrical 
Impedance Analysis, the skeletal muscle index, the body mass index, the waist circumference 
and gives nutritional advice to reduce weight and inflammation [51]. According to this care 
model the nurse specialist assesses vital signs and collects blood sample to evaluate traditional 
acute phase reactants, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) 
and cytokine levels. Moreover, the nurse helps clinicians evaluating tender and swollen joints 
and evaluates different aspects of patients’ health through patient-reported outcomes (PRO) 
measures to assess also patients’ physical function, fatigue and the impact of the disease on 
their quality-of-life [52]. According to this new model of care patients affected by Psoriatic 
Arthritis and their caregivers receive also educational advice by the nurse specialist to improve 








Fig 5 The Multidimensional Assessment of PsA patients 
 
2.1 Patient-reported Outcomes Measures (PROMs) in PsA 
To ensure the best possible evaluation of patients affected by PsA, and on the basis of 
physicians’ and patients’ perspectives, the Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA) together with the Outcome Measures in Rheumatology 
(OMERACT) international consensus created a core outcome set (COS) that should be 
measured at each patients’ assessment [53]. Patient-reported outcome measures (PROMs) are 
used to assess the global and domain-related in patients with PsA [54]. According to the two 
groups the most important domains to evaluate are: musculoskeletal disease activity, skin 
disease activity, patient global assessment, physical function, fatigue and the impact of the 
disease on patients’ quality-of-life. PROMs include different tools that nurses can use in their 
practice. According to this, in the multiprofessional model of care, the nurse specialist evaluates 
patients’ pain with the Visual Analogue Scale (VAS) and patients’ function disability using the 
Health Assessment Questionnaire (HAQ). To assess the impact of the disease on life the nurse 
uses the Psoriatic Arthritis Impact of Disease Questionnaire (PsAID). The functional 
assessment of chronic illness therapy-fatigue scale (FACIT-fatigue) was selected to assess 
patients’ fatigue in the multidimensional evaluation. To evaluate patients’ mood, the Patient 
Health Questionnaire-9 (PHQ-9) is used as a screening tool for depression.  
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Chapter 3: Relationship between clinical variables and Patient -




Psoriatic arthritis (PsA) is an axial and/or peripheral chronic inflammatory arthritis associated 
with psoriasis, enclosed in the group of spondylarthritis. It is characterized by distal 
interphalangeal joint involvement, asymmetric distribution of arthritis, dactylitis, enthesitis, 
spinal involvement, and a frequent association with HLA-B27.  Genetic, environmental, and 
immunological factors seem to contribute to its development. PsA is strongly associated with 
obesity, metabolic syndrome, cardiovascular disease and other comorbidities beyond joint and 
skin manifestations, so, patients need to be assessed both from rheumatologists and 
dermatologists with other healthcare professionals’ support to have a more comprehensive 
evaluation than the standard assessment. A global assessment is important to improve their 
disease control and their quality-of-life. A new model of care for PsA patients is the 
multidimensional assessment that allows to evaluate patients globally paying attention to 
different aspect of the disease. Differently from the standard practice, in a multidimensional 
assessment a multidisciplinary team (rheumatologist, dermatologist, internal medicine 
physician, nutritionist and a phycologist) with a nurse as case manager, assess patients from the 
admission to the follow-up. According to the GRAPPA and OMERACT groups different 
validated tools are used by the team to patient-reported-outcomes for fatigue, the impact of 
disease on quality-of-life, functional disability, disease activity and mood are evaluated by the 
team. Joint and skin are evaluated with specific tools [54].  
 
2.2 Aim of the study 
This study aimed to evaluate the association between and among clinical variables and Patient-
Reported Outcomes in a real-world sample of PsA patients.   
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2.3 Materials and Methods 
A new model of care (The Multidimensional Assessment for PsA patients) was developed to 
globally evaluate patients at the Department of Internal Medicine with Rheumatology and 
Dermatology of the National Relevance and High Specialization Hospital Trust ARNAS 
Civico, Di Cristina, Benfratelli in Palermo (Italy). A cross-sectional study was carried out from 
March 2018 to October 2020. Eligible patients were all the outpatients with Psoriatic Arthritis 
diagnosis according to CASPAR criteria, aged > 18 years, who signed the informed consent to 
be enrolled in the study. According to the Multidimensional assessment each patient was 
evaluated in the same setting by a multidisciplinary team made by rheumatologist, 




Patients signed informed consent before their inclusion in the study. The Ethics committee 
Palermo2 approved the study with protocol number 231 CIVICO 2018. The study was 
conducted according to the Good Clinical Practice in accordance with the ethical standards laid 
down in the 1964 Declaration of Helsinki and its later amendments. Medical practice was 
performed as stated by the recommendations of the World Medical Assembly. Data privacy 
was a guarantee by the Personal Data Protection Code (196/2003) and current regulations.   
 
2.3.2 Data collection 
A data collection form and a database were created in order to collect different variables from 
patients. The Core Outcome Set (COS) validated by the Group for Research and Assessment 
of Psoriasis and Psoriatic Arthritis (GRAPPA) with the Outcome Measures in Rheumatology 
(OMERACT) international consensus was used as a guide to selecting tools. Data included in 
this study were: 
• Socio-demographic data; 
• Data about smoking and alcohol consumption; 
• Data about family members and caregivers;  
• The Health Assessment Questionnaire (HAQ) to assess functional disability; 
• The Facit-Fatigue (FACIT-F) to evaluate fatigue;  
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• The Psoriatic Arthritis Impact of Disease Questionnaire (PsAID) to investigate about 
the impact of the disease in patients’ quality-of-life;  
• The Patient Health Questionnaire-9 (PHQ-9) to evaluate mood and screen depression; 
• The Disease Activity in PSoriatic Arthritis score (Dapsa) to assess joint manifestations, 
pain and disease activity;  
• The Patient global assessment (PGA) 
• Body Mass Index (BMI) 
• Waist circumference  
• Complete blood panel (clinical chemistry, lipid and metabolic panel, complete blood 
count, cytokine levels, liver function, ESR, CRP) 
 
2.3.3 Statistical Analysis 
STATA (StataCorp.2016. Stata Statistical Software: Release 14.1, College Station, TX, USA: 
StataCorp LP) was used for database management and analysis. The statistical analysis was 
performed using the logistic analysis to study the relationships among all the variables. In 
particular, a logistic analysis was performed between moderate to severe functional disability 
(HAQ >2) and central obesity as an independent variable and among the high impact of disease 
(PsAID >4) as a dependent variable and central obesity as an independent variable. Odds ratios 
(ORs) and 95% confidence intervals (95%CIs) were computed. A two-tailed p<0,05 was 
considered statistically significant.  
2.4 Results 
 
According to CASPAR criteria, 158 patients aged 55.2 (53.3 – 57.1) (Fig 6), affected by 
Psoriatic Arthritis were consecutively enrolled and evaluated. Both sexes were equally 
represented. Less than half of the sample do not have a caregiver that is a person who takes care 
of the patient and only the 31% of included patients attended the high school. Most of them, 
especially men, attended the elementary or the middle school and this was an important barrier 
in nursing education during the assessment. Data about the family member were collected to 
assess the disease burden especially for mothers or fathers who take cares of loved ones despite 
joint manifestations and the pain. The 24,7% were smokers and only the 5,7% consumed a 
regular amount of alcohol every day. The average years of illness were 10.6 (9.3-11.9). 












































The specialist nurse evaluated patients with different PROMs including the Health Assessment 
Questionnaire (HAQ), the Facit-Fatigue (FACIT-F), the Psoriatic Arthritis Impact of Disease 
Questionnaire (PsAID) and the Patient Health Questionnaire-9 (PHQ-9). 
Some drugs for PsA are associated with an increased risk of psychiatric symptoms, including 
depression, suicidal thoughts or suicidal behaviours if patients had a history of depression. For 
this reason, PHQ-9 was used as a screening tool to investigate about patients’ mood and to 
screen depression. According to PHQ-9, the 40% of the enrolled sample had from moderate to 










The Health Assessment Questionnaire (HAQ) was used to assess if patients had discomfort or 
were unable to do some daily movement as dressing, arising, eating, walking, hygiene, reach, 
grip, and activities in which joints are involved.  
The average HAQ was 1 (0.25 - 1.75), and data analysis showed 51% of patients with normal-
mild functional disability, 31% moderate to severe disability, and 18% severe to very severe 


















Fatigue in PsA patients is a synonymous of weakness and lack of motivation. It is 
underestimated and not often included in the standard assessment but it has implication for 
patients in terms of loss of employment, social isolation and decreased quality-of-life due to 
disease. In the Multidimensional assessment patients’ fatigue was evaluated with the FACIT-F 
questionnaire that showed the 42,4% of the sample with high fatigue (fig 9). 
 
Fig. 9 Facit–Fatigue 
 
 
Psoriatic Arthritis negatively impact on patients’ quality of life, in fact, 52.5% of the sample 
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Data analysis showed that the 81.3% of the sample was treated with biological therapy (69% 
anti TNF- alfa, 1% anti IL-23, 4% anti IL12-23, 13% anti IL 17, and 13% small molecules) (fig 
11). 
 



















41.6% of patients were treated with DMARDS (78% methotrexate, 10% leflunomide, 7% 
salazopyrin, 5% cyclosporine) (fig 12) while some of them were treated with combinations of 
both biologics and DMARDs. 
 
Fig 12 patients treated with DMARDS 
 
 
From all the collected variables important observations came out from the anthropometric 
assessment. 70.2% of the 158 enrolled patients had central obesity (61.1% men and 77.9% 
women) with an average waist circumference of 104.3 (101 – 107.5) for women and 105.5 
(102.5 -108.5) for men. Central obesity occurs when there is excessive central fat around the 
stomach and was measured as waist circumference (cm). It is known that increased obesity-
related health risks are associated with a waist circumference greater or equal to 94 cm in men 
and 80 cm in women and the mean waist circumference for both sexes was 104,8 (102,6 – 































The Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height 
in meters, and it is an indicator of body fatness. In the enrolled sample, the mean BMI was 28,9 
(28,0 – 29,8) as showed in figure 12.  Normal or healthy weight ranges from 18.5 to 24.9, 
instead, according to the BMI weight status categories, people with a BMI that ranges from 25 
to 29.9 would be classified as overweight so the studied population can be classified as 
overweight.  
 




Tab 4. Anthropometric data of the sample 
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Patients were divided by subgroups as affected by central obesity or without central obesity as 
shown in table 5.  
 
Tab 5 population with central obesity or without central obesity 
 
 
Patients affected by 
Central Obesity (n=111) 
Patients without Central 
Obesity (n=47) 
p 
Men (%) 39,6 59,6 0.0214 
Age* 57,2 (54,9 – 59,4) 50,4 (47,3 – 53,6) 0.0011 
Years of illness* 10,8 (9,3 – 12,3) 10,0 (7,5 – 12,5) 0.4623 
Smokers(%) 23,4 27,7 0.5724 
Alcohol Consumption(%) 7,3 2,1 0.2041 
 
 
All the collected variables were associated with PROMs with the statistical analysis and a 
strong association was observed between functional disability measured by HAQ >2 and central 
obesity [OR (95% CI) 16.94 (2.22 - 129.48); p < 0.004]. Moreover, data analysis showed an 
association between high impact of disease on life (PsAID >4) and central obesity [OR (95% 
CI) 3.33 (1.56 - 7.13); p<0,002]. Models were adjusted for age, sex, years of illness, and 

























Psoriatic Arthritis is a disease treated both from rheumatologists and dermatologists and 
guidelines on this topic approach the management of the disease from different perspectives.  
EULAR guidelines [56] are more focused on pharmacological treatments for musculoskeletal 
manifestations, and only in cases of substantial skin or nail bed manifestations EULAR 
recommends working closely with a dermatologist. Even if the GRAPPA recommendations 
[57] were developed by consensus among the two specialists, PsA patients have usually more 
than one comorbid condition in addition to the skin and joint diseases so, they need to have a 
more comprehensive assessment. As Visalli et al. said PsA can be optimally treated by a 
multidisciplinary approach so the multidimensional assessment represents a new model of care 
that allows patients to receive the best possible quality of care [58]. The multiprofessional team 
evaluated skin and joint manifestation, pain and disease activity, anthropometric measures, 
physical function, fatigue and the impact of the disease on patients’ quality-of-life. Psoriatic 
Arthritis is an inflammatory disease, and all the others inflammatory conditions may affect 
patient outcomes. One of the most important observation during the three years of patients’ 
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examination was about the quality-of-life in patients with high waist circumferences so we 
aimed to study the association among central obesity and the role of central obesity as a 
predictor of high impact of disease on quality-of-life and disease activity. Corrao et al. 
highlighted the role of central obesity in increasing the inflammatory status. According to the 
authors, central obesity occurs when there is an excessive intra-abdominal visceral fact and has 
been strongly linked to cardiovascular disease. Visceral adipose Tissue was considered to be a 
storage organ for fatty acids without other functions, but nowadays in particular the visceral 
one is considered a metabolically active endocrine organ. In fact, it represents a source of 
inflammatory mediators, known as adipokines, including leptin and adiponectin, plasminogen 
activator inhibitor-1 (PAI-1), TNF-α, macrophage chemoattractant protein-1, IL-6, leading to a 
pro-inflammatory status in obese subjects [59-61]. TNF is overexpressed in the adipose tissue 
that links obesity, diabetes and chronic inflammation [62]. In addition, obesity promotes 
expansion of Th17 cells in adipose tissue and peripheral tissues [63]. For all these reasons, 
obesity is considered as a low-grade inflammatory disease and, in particular, central obesity 
may also determine an increased risk of not achieving and maintaining minimal disease activity 
(MDA) in PsA patients [64]. Inflammation affects joints and reduces patients’ ability. This 
study demonstrated that patients with central obesity have functional disability and a high 
impact of the disease on their quality-of-life. Data suggest that a multiprofessional evaluation 
for these patients is important to evaluate different aspect of the disease as the comorbidities 




















Conclusion and future prospective 
 
This study demonstrated that this new model of care (The Multidimensional Assessment) for 
these patients is important to evaluate different aspect of the disease as the comorbidities. In 
particular, therapeutic goals should not be focused only on treatment but also on waist 
circumference reduction to reduce inflammation and improve patients’ functional ability and 
quality-of-life. Further research is needed to study the relationship between serum cytokine 
levels and clinical variables in PsA patients according to their treatment to find the correct drug. 
Serum samples were collected at the same time of patients’ evaluations and stored. The 
MAGPIX® system will analyze serum cytokine levels. This system will use customized 
magnetic bead-based multi-analyte panels, as a novel protein array system denoted as multiplex 
cytokine assay, to simultaneously measure the levels of 10 circulating cytokines of patients 
with PsA. We will analyze: COMP, IL-2, IL-4, IL-6, IL-10, IL-17A (CTLA-8), IL-23, M-CSF, 





























List of abbreviations 
 
Classification Criteria for Psoriatic Arthritis = (CASPAR) 
Confidence Interval = (CI) 
Disease modifying antirheumatic drugs = (DMARDS) 
Health Assessment Questionnaire = (HAQ) 
Human leukocyte antigen complex = (HLA)  
Minimal disease activity =(MDA) 
Nonsteroidal anti-inflammatory drugs = (NSAID) 
Odd Ratio = (OR) 
Plasminogen activator inhibitor-1 = (PAI-1) 
Psoriasis Area Severity Index = (PASI) 
Psoriatic Arthritis = (PsA)  
Psoriatic Arthritis Impact of Disease = (PsAID) 
Tumor necrosis factor = TNF α 
T-helper cell=Th  
Regulatory T cell=Treg  
Innate lymphoid cell= ILC 
 Mucosal-associated invariant T= MAIT 
 NK=natural killer 
TNF superfamily member 11=RANKL 
Interferon γ=IFNγ 
 Interleukin=IL  
Transforming growth factor β=TGFβ 
 C-C motif chemokine ligand 5=RANTES 
Oncostatin M= OSM 
Granulocyte-macrophage colony-stimulating factor=GM-CSF 
Reactive oxygen species=ROS 
Nitric oxide=NO 
Matrix metalloproteinases=MMPs 
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